GlassScriptPhysician profile
Ushama Patel
NPI 1154447738
$1,683.69
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $247 · 2021: $130 · 2022: $370 · 2023: $256 · 2024: $13.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.01 | 2021-2023 | |
| Neos Therapeutics, LP | $180.73 | 2019-2020 | |
| Allergan, INC. | $173.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.41 | 2019-2022 | |
| Corium, LLC | $150.60 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $124.75 | 2019-2023 | Rexulti |
| Lundbeck LLC | $70.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $66.22 | 2019-2024 | Austedo Xr |
| Alkermes, INC. | $64.55 | 2022 | |
| Neurocrine Biosciences, INC. | $62.68 | 2022-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $55.18 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.42 | 2022 | |
| Adlon Therapeutics L.P. | $38.05 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $36.38 | 2019 | |
| Vertical Pharmaceuticals, LLC | $33.55 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $23.80 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $22.25 | 2019 | |
| Axsome Therapeutics, INC. | $19.51 | 2023 | Auvelity |
| Supernus Pharmaceuticals, INC. | $15.12 | 2023 | Qelbree |
| Shire North American Group INC | $12.88 | 2019 | |
| Tris Pharma INC | $11.67 | 2019 | |
| Neuronetics, INC. | $8.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ushama Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.